Developer docs
API playgroundTry for free, no card

Search company profiles

Apple Tree Partners

Full company profile

uuid00005x4

Namestring
Apple Tree Partners
Legal namestring
ATP Life Science Ventures, L.P.
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Apple Tree Partners (ATP) is a life sciences venture capital firm founded in 1999 by Seth L. Harrison, MD, headquartered in New York with additional offices in Cambridge, South San Francisco, London, and Branford, Connecticut. The firm creates and invests in biotechnology companies across modalities including RNA exon editing (Ascidian Therapeutics), self-replicating RNA (Replicate Bioscience), IL-2 therapeutics (Aulos Bioscience), T-cell receptor targeting (Marengo Therapeutics), pulsed electric field ablation (Galvanize Therapeutics), selective protein-synthesis termination (Initial Therapeutics), AI-driven drug discovery (Deep Apple Therapeutics), and opioid-use-disorder treatment (Braeburn). ATP supports approximately 30 portfolio companies spanning pre-IP ideation through IPO, drawing on $2.65 billion in committed capital, an in-house ATP R&D Labs facility in Branford for preclinical research, and a team of venture partners with prior leadership roles at Pfizer, Eli Lilly, Amgen, Biogen, Novartis, and Sanofi Genzyme.

The firm's revenue model is traditional venture capital: management fees on committed capital plus carried interest on successful exits. Documented realizations include Akero Therapeutics acquired by Novo Nordisk for up to $5.2 billion, Chinook Therapeutics acquired by Novartis for $3.2 billion, and prior exits to Medtronic (HeartWare), Abbott (Tendyne), Alexion (Syntimmune), and Johnson & Johnson (VytronUS). In December 2025, ATP Life Science Ventures, L.P. filed for voluntary Chapter 11 bankruptcy in Delaware following a dispute with major limited partner Rigmora Holdings (the Rybolovlev family trust) over capital-call obligations, despite reporting assets exceeding $1 billion against liabilities of less than $500,000. The Delaware Chancery Court subsequently ordered Rigmora to pay $97 million, and Oaktree Capital Management is evaluating a $300 million investment as part of a potential reorganization.

Customer segments are two-sided: life-sciences entrepreneurs and academic founders seeking pre-IPO capital and company-creation infrastructure on one side, and institutional investors and family offices seeking life-sciences venture exposure on the other. The firm goes to market primarily through direct networking, scientific advisory relationships, industry-conference presence (ASCO, AACR, ASGCT, J.P. Morgan Healthcare Conference), and the visible clinical and commercial progress of its portfolio companies, rather than traditional marketing channels.

Short descriptiontext

Apple Tree Partners is a life sciences venture capital firm founded in 1999 that creates and funds biotechnology companies from pre-IP ideas through IPO. It manages $2.65 billion in committed capital across approximately 30 portfolio companies spanning RNA editing, srRNA, TCR therapy, PEF ablation, and AI-driven drug discovery for institutional LPs and biotech founders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotechnology investment, pharmaceutical venture funding, healthcare innovation capital, biotech company creation
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Venture Capital Fund Management
TypeLicensing Royalties
Description

ATP generates returns through equity ownership in portfolio companies. The firm manages multiple fund vehicles with committed capital from limited partners and earns management fees and carried interest on successful exits.

appletreepartners.com
2Portfolio Company Equity
TypeLicensing Royalties
Description

Direct equity investments in life sciences companies from seed through IPO and beyond, with successful exits including acquisitions by Novo Nordisk (Akero Therapeutics for $5.2B, Corvidia Therapeutics), Medtronic (HeartWare International), Abbott (Tendyne), Alexion (Syntimmune), and others.

forbes.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Apple Tree Partners (ATP) is a life sciences venture capital firm that creates and invests in biotechnology and medical technology companies, from pre-IP ideas and asset spinouts through seed stage to IPO and beyond. The firm provides flexible capital, strategic insight, and operational resources to its portfolio, including in-house R&D services through ATP R&D Labs in New Haven, Connecticut.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Akero Therapeutics acquired by Novo Nordisk for up to $5.2 billion
+2 more records
Product overview1 text field

Apple Tree Partners (ATP) is a life sciences venture capital firm founded in 1999 that creates and invests in biotechnology companies starting at various stages from pre-IP ideas to asset spinouts. ATP does not offer a single unified product but rather operates a portfolio of portfolio companies across multiple therapeutic areas including oncology (Aulos Bioscience, Marengo Therapeutics, Aethon Therapeutics), genetic medicine (Ascidian Therapeutics, Initial Therapeutics), infectious disease (Replicate Bioscience, Red Queen Therapeutics), medical devices (Galvanize Therapeutics), CNS/addiction (Braeburn, Nine Square Therapeutics), and others. ATP provides flexible capital, strategic insight, and operational resources through its team of venture partners and in-house ATP R&D Labs facility. The portfolio spans from seed stage through IPO and beyond, with companies at various stages from preclinical to commercialized products like Braeburn's BRIXADI.

Product and service2 records
1Life Sciences Venture Capital Fund Management
CategoryVenture Capital Fund Management
Description

Management of life sciences-focused venture capital fund vehicles (e.g., ATP Life Science Ventures, L.P.) with $2.65 billion in committed capital, providing equity capital and strategic support to biotech and medtech companies from seed through IPO.

2ATP R&D Labs
CategoryInternal R&D / Incubator Services
Description

In-house incubator and accelerator facility in New Haven/Branford, Connecticut offering compound screening, cellular and molecular assays, data analytics, and preclinical pharmacology services to ATP portfolio companies, using in vivo and in vitro methodologies to discover and evaluate small molecules.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Ascidian Therapeutics (ATP portfolio company) entered a global research collaboration and licensing agreement with Lilly to discover and develop RNA exon editor therapies for undisclosed monogenic kidney diseases. Ascidian is eligible to receive up to $1.9 billion including upfront, development and commercial milestone payments, and tiered royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-20
Description

Marengo Therapeutics entered multi-year collaboration with University of Pennsylvania Institute for Immunology and Immune Health to advance next wave precision T cell immunology research in oncology and autoimmune diseases.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-08
Description

Replicate Bioscience entered partnership with Novo Nordisk to unlock self-replicating RNA therapies for obesity and diabetes. Also, Deep Apple Therapeutics announced collaboration with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-07
Description

Ascidian Therapeutics and Forge Biologics announced manufacturing partnership to advance RNA editing therapy for Stargardt disease.

5Instituto Butantan
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-04
Description

Replicate Bioscience entered collaborative agreement with Instituto Butantan to develop and commercialize Replicate's self-replicating RNA (srRNA) rabies vaccine in Latin America.

appletreepartners.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-13
Description

Marengo Therapeutics announced clinical study collaboration with Gilead Sciences to evaluate Invikafusp alfa (STAR0602) and Trodelvy in both metastatic TNBC and metastatic HR+/HER2- breast cancers.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-06-18
Description

Ascidian Therapeutics entered collaboration with Roche for discovery and development of RNA exon editing therapeutics targeting neurological diseases.

8Merck KGaA, Darmstadt, Germany
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-11
Description

Aulos Bioscience entered clinical trial collaboration and supply agreement with Merck KGaA to study combination of Bavencio with AU-007.

appletreepartners.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-06-07
Description

Ipsen and Marengo Therapeutics announced second strategic partnership to advance precision T cell engagers from Marengo's Tri-STAR platform. Second drug candidate nomination from strategic collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-09
Description

ATP and NYU Langone Health co-founded Aethon Therapeutics with $30M Series A ($25M from ATP). Research partnership with NYU Langone's Perlmutter Cancer Center for HapImmune immunotherapy platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded Aulos Bioscience with Biolojic Design, which provides AI/machine learning capabilities for antibody design. Biolojic Design's computational platform designed AU-007.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest dedicated healthcare-focused investment firms globally, investing across biopharmaceuticals, medical devices, and diagnostics. Directly comparable to ATP in life sciences venture mandate, fund size, and company-creation approach.

TypeDirect peer
Description

Early-stage life sciences venture firm that builds biotech companies from inception. Direct peer to ATP's company-creation model, with similar therapeutic breadth and focus on seed/Series A formation rounds.

TypeDirect peer
Description

Healthcare-focused venture firm with dedicated in-house discovery engine (Inception Sciences) mirroring ATP R&D Labs. Direct peer on company-creation model and multi-modality biotech investing.

TypeDirect peer
Description

Pioneering biotech VC firm creating and backing breakthrough life sciences companies from inception through IPO. Comparable to ATP in scale, scientific depth, and long-duration company-building approach.

TypeDirect peer
Description

Healthcare venture firm that builds biotech companies around innovative science. Direct peer in the company-creation model, with strong academic founder networks and full operational support model.

TypeDirect peer
Description

Early-stage life sciences venture firm investing in platform technologies and therapeutic assets. Comparable to ATP in fund size, stage focus, and broad therapeutic-area coverage.

TypeDirect peer
Description

Life sciences-focused investment firm with crossover fund capabilities. Direct peer for late-stage private/public biotech investing and is also a frequent co-investor with life sciences VCs.

TypeDirect peer
Description

Biotech company-creation platform that originates and grows breakthrough life sciences companies. Direct peer to ATP's company-creation model, with comparable in-house R&D infrastructure and multi-modality investment approach.

TypeBroad incumbent
Description

One of the largest venture firms globally with a dedicated healthcare practice. Broader incumbent investor with overlapping life sciences activity across stages and modalities.

TypeBroad incumbent
Description

Multi-stage venture firm with a meaningful life sciences practice. Broader incumbent with comparable biotech deal activity but less concentrated than pure-play life sciences VCs like ATP.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries15 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment79 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apple Tree Partners

Life Sciences Venture Capitalappletreepartners.com

Apple Tree Partners is a life sciences venture capital firm founded in 1999 that creates and funds biotechnology companies from pre-IP ideas through IPO. It manages $2.65 billion in committed capital across approximately 30 portfolio companies spanning RNA editing, srRNA, TCR therapy, PEF ablation, and AI-driven drug discovery for institutional LPs and biotech founders.

What Apple Tree Partners does

Apple Tree Partners (ATP) is a life sciences venture capital firm founded in 1999 by Seth L. Harrison, MD, headquartered in New York with additional offices in Cambridge, South San Francisco, London, and Branford, Connecticut. The firm creates and invests in biotechnology companies across modalities including RNA exon editing (Ascidian Therapeutics), self-replicating RNA (Replicate Bioscience), IL-2 therapeutics (Aulos Bioscience), T-cell receptor targeting (Marengo Therapeutics), pulsed electric field ablation (Galvanize Therapeutics), selective protein-synthesis termination (Initial Therapeutics), AI-driven drug discovery (Deep Apple Therapeutics), and opioid-use-disorder treatment (Braeburn). ATP supports approximately 30 portfolio companies spanning pre-IP ideation through IPO, drawing on $2.65 billion in committed capital, an in-house ATP R&D Labs facility in Branford for preclinical research, and a team of venture partners with prior leadership roles at Pfizer, Eli Lilly, Amgen, Biogen, Novartis, and Sanofi Genzyme.

The firm's revenue model is traditional venture capital: management fees on committed capital plus carried interest on successful exits. Documented realizations include Akero Therapeutics acquired by Novo Nordisk for up to $5.2 billion, Chinook Therapeutics acquired by Novartis for $3.2 billion, and prior exits to Medtronic (HeartWare), Abbott (Tendyne), Alexion (Syntimmune), and Johnson & Johnson (VytronUS). In December 2025, ATP Life Science Ventures, L.P. filed for voluntary Chapter 11 bankruptcy in Delaware following a dispute with major limited partner Rigmora Holdings (the Rybolovlev family trust) over capital-call obligations, despite reporting assets exceeding $1 billion against liabilities of less than $500,000. The Delaware Chancery Court subsequently ordered Rigmora to pay $97 million, and Oaktree Capital Management is evaluating a $300 million investment as part of a potential reorganization.

Customer segments are two-sided: life-sciences entrepreneurs and academic founders seeking pre-IPO capital and company-creation infrastructure on one side, and institutional investors and family offices seeking life-sciences venture exposure on the other. The firm goes to market primarily through direct networking, scientific advisory relationships, industry-conference presence (ASCO, AACR, ASGCT, J.P. Morgan Healthcare Conference), and the visible clinical and commercial progress of its portfolio companies, rather than traditional marketing channels.

Apple Tree Partners firmographics

Firmographics
Name
Apple Tree Partners
Legal name
ATP Life Science Ventures, L.P.
Website
https://appletreepartners.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Apple Tree Partners is a life sciences venture capital firm founded in 1999 that creates and funds biotechnology companies from pre-IP ideas through IPO. It manages $2.65 billion in committed capital across approximately 30 portfolio companies spanning RNA editing, srRNA, TCR therapy, PEF ablation, and AI-driven drug discovery for institutional LPs and biotech founders.
Ownership category
akta.pro rank

Where Apple Tree Partners is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Apple Tree Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Venture Capital Fund Management: ATP generates returns through equity ownership in portfolio companies. The firm manages multiple fund vehicles with committed capital from limited partners and earns management fees and carried interest on successful exits.
  2. Portfolio Company Equity: Direct equity investments in life sciences companies from seed through IPO and beyond, with successful exits including acquisitions by Novo Nordisk (Akero Therapeutics for $5.2B, Corvidia Therapeutics), Medtronic (HeartWare International), Abbott (Tendyne), Alexion (Syntimmune), and others.

Go-to-market motion1 record

Marketing channels3 records

Apple Tree Partners product offering

Product offering

Core offering

Apple Tree Partners (ATP) is a life sciences venture capital firm that creates and invests in biotechnology and medical technology companies, from pre-IP ideas and asset spinouts through seed stage to IPO and beyond. The firm provides flexible capital, strategic insight, and operational resources to its portfolio, including in-house R&D services through ATP R&D Labs in New Haven, Connecticut.

Product overview

Apple Tree Partners (ATP) is a life sciences venture capital firm founded in 1999 that creates and invests in biotechnology companies starting at various stages from pre-IP ideas to asset spinouts. ATP does not offer a single unified product but rather operates a portfolio of portfolio companies across multiple therapeutic areas including oncology (Aulos Bioscience, Marengo Therapeutics, Aethon Therapeutics), genetic medicine (Ascidian Therapeutics, Initial Therapeutics), infectious disease (Replicate Bioscience, Red Queen Therapeutics), medical devices (Galvanize Therapeutics), CNS/addiction (Braeburn, Nine Square Therapeutics), and others. ATP provides flexible capital, strategic insight, and operational resources through its team of venture partners and in-house ATP R&D Labs facility. The portfolio spans from seed stage through IPO and beyond, with companies at various stages from preclinical to commercialized products like Braeburn's BRIXADI.

Differentiator

Problem solved

Functional benefit

Products and services

  • Life Sciences Venture Capital Fund Management Management of life sciences-focused venture capital fund vehicles (e.g., ATP Life Science Ventures, L.P.) with $2.65 billion in committed capital, providing equity capital and strategic support to biotech and medtech companies from seed through IPO.
  • ATP R&D Labs In-house incubator and accelerator facility in New Haven/Branford, Connecticut offering compound screening, cellular and molecular assays, data analytics, and preclinical pharmacology services to ATP portfolio companies, using in vivo and in vitro methodologies to discover and evaluate small molecules.

Quantifiable outcome

  • Akero Therapeutics acquired by Novo Nordisk for up to $5.2 billion
  • +2 more outcomes

Companies that use Apple Tree Partners

Customer profile

Segments2 records

Ideal customer profiles2 records

Apple Tree Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Apple Tree Partners partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered major and core.

  • Eli Lilly and CompanymajorStrategic or Co-development Partner · 3 June 2026Ascidian Therapeutics (ATP portfolio company) entered a global research collaboration and licensing agreement with Lilly to discover and develop RNA exon editor therapies for undisclosed monogenic kidney diseases. Ascidian is eligible to receive up to $1.9 billion including upfront, development and commercial milestone payments, and tiered royalties.
  • University of Pennsylvania Institute for Immunology and Immune HealthcoreStrategic or Co-development Partner · 20 March 2025Marengo Therapeutics entered multi-year collaboration with University of Pennsylvania Institute for Immunology and Immune Health to advance next wave precision T cell immunology research in oncology and autoimmune diseases.
  • Novo NordiskmajorStrategic or Co-development Partner · 8 January 2025Replicate Bioscience entered partnership with Novo Nordisk to unlock self-replicating RNA therapies for obesity and diabetes. Also, Deep Apple Therapeutics announced collaboration with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases.
  • Forge BiologicscoreTechnology or Integration · 7 January 2025Ascidian Therapeutics and Forge Biologics announced manufacturing partnership to advance RNA editing therapy for Stargardt disease.
  • Instituto ButantancoreChannel Partner/ Reseller/ Distributor · 4 December 2024Replicate Bioscience entered collaborative agreement with Instituto Butantan to develop and commercialize Replicate's self-replicating RNA (srRNA) rabies vaccine in Latin America.
  • Gilead SciencescoreStrategic or Co-development Partner · 13 September 2024Marengo Therapeutics announced clinical study collaboration with Gilead Sciences to evaluate Invikafusp alfa (STAR0602) and Trodelvy in both metastatic TNBC and metastatic HR+/HER2- breast cancers.
  • RochemajorStrategic or Co-development Partner · 18 June 2024Ascidian Therapeutics entered collaboration with Roche for discovery and development of RNA exon editing therapeutics targeting neurological diseases.
  • Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development Partner · 11 June 2024Aulos Bioscience entered clinical trial collaboration and supply agreement with Merck KGaA to study combination of Bavencio with AU-007.
  • IpsenmajorStrategic or Co-development Partner · 7 June 2024Ipsen and Marengo Therapeutics announced second strategic partnership to advance precision T cell engagers from Marengo's Tri-STAR platform. Second drug candidate nomination from strategic collaboration.
  • NYU Langone Health / Perlmutter Cancer CentercoreStrategic or Co-development Partner · 9 January 2023ATP and NYU Langone Health co-founded Aethon Therapeutics with $30M Series A ($25M from ATP). Research partnership with NYU Langone's Perlmutter Cancer Center for HapImmune immunotherapy platform.
  • Biolojic DesigncoreStrategic or Co-development PartnerCo-founded Aulos Bioscience with Biolojic Design, which provides AI/machine learning capabilities for antibody design. Biolojic Design's computational platform designed AU-007.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Apple Tree Partners competitors and assessment

Company assessment

Direct peers

  • OrbiMed: One of the largest dedicated healthcare-focused investment firms globally, investing across biopharmaceuticals, medical devices, and diagnostics. Directly comparable to ATP in life sciences venture mandate, fund size, and company-creation approach.
  • Atlas Venture: Early-stage life sciences venture firm that builds biotech companies from inception. Direct peer to ATP's company-creation model, with similar therapeutic breadth and focus on seed/Series A formation rounds.
  • Versant Ventures: Healthcare-focused venture firm with dedicated in-house discovery engine (Inception Sciences) mirroring ATP R&D Labs. Direct peer on company-creation model and multi-modality biotech investing.
  • ARCH Venture Partners: Pioneering biotech VC firm creating and backing breakthrough life sciences companies from inception through IPO. Comparable to ATP in scale, scientific depth, and long-duration company-building approach.
  • Third Rock Ventures: Healthcare venture firm that builds biotech companies around innovative science. Direct peer in the company-creation model, with strong academic founder networks and full operational support model.
  • 5AM Ventures: Early-stage life sciences venture firm investing in platform technologies and therapeutic assets. Comparable to ATP in fund size, stage focus, and broad therapeutic-area coverage.
  • RA Capital Management: Life sciences-focused investment firm with crossover fund capabilities. Direct peer for late-stage private/public biotech investing and is also a frequent co-investor with life sciences VCs.
  • Flagship Pioneering: Biotech company-creation platform that originates and grows breakthrough life sciences companies. Direct peer to ATP's company-creation model, with comparable in-house R&D infrastructure and multi-modality investment approach.

Broad incumbents

  • New Enterprise Associates (NEA): One of the largest venture firms globally with a dedicated healthcare practice. Broader incumbent investor with overlapping life sciences activity across stages and modalities.
  • Bessemer Venture Partners: Multi-stage venture firm with a meaningful life sciences practice. Broader incumbent with comparable biotech deal activity but less concentrated than pure-play life sciences VCs like ATP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Apple Tree Partners social profiles

Digital presence

Apple Tree Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apple Tree Partners leadership team

Management profile

Number of profiles

Profiles21 records

Apple Tree Partners subsidiaries and ownership

Company hierarchy

Subsidiaries15 records

Apple Tree Partners funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apple Tree Partners M&A and investment

M&A and investment

M&A

Investments79 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apple Tree Partners

What does Apple Tree Partners do?

Apple Tree Partners (ATP) is a life sciences venture capital firm that creates and invests in biotechnology and medical technology companies, from pre-IP ideas and asset spinouts through seed stage to IPO and beyond. The firm provides flexible capital, strategic insight, and operational resources to its portfolio, including in-house R&D services through ATP R&D Labs in New Haven, Connecticut.

Is Apple Tree Partners a public or private company?

Apple Tree Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Apple Tree Partners founded?

Apple Tree Partners was founded in 1999. It employs 11 to 50 people.

Where is Apple Tree Partners based?

Apple Tree Partners is headquartered in New York, United States, in the North America region.

How does Apple Tree Partners make money?

Two revenue lines are on record. Venture Capital Fund Management is the primary driver. The others are portfolio Company Equity.

Who are Apple Tree Partners's main competitors?

Direct peers on record are OrbiMed, Atlas Venture, Versant Ventures, ARCH Venture Partners, Third Rock Ventures, 5AM Ventures, RA Capital Management and Flagship Pioneering. Broad incumbents are New Enterprise Associates (NEA) and Bessemer Venture Partners.

Does Apple Tree Partners have an API?

No public API is recorded for Apple Tree Partners.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioPharma DiveJudge orders Apple Tree partner to forfeit oversight of venture fundA Cayman Islands court has ordered Seth Harrison, general partner of biotech venture capital firm Apple Tree Partners (ATP), to forfeit control of the fund, potentially handing management to two court-appointed independent directors from Alvarez & Marsal. The ruling is the culmination of a dispute between ATP and its primary backer Rigmora Biotech Investors, associated with Russian billionaire Dmitry Rybolovlev, over capital commitments and alleged fund mismanagement. ATP has filed for Chapter 11 bankruptcy protection in Delaware while pursuing a restructuring plan that would allow it to continue funding portfolio companies, with Harrison emerging as a bidder for those startups.Crain CurrencyRussian billionaire wins fight to boot manager of biotech fundRussian billionaire Dmitry Rybolovlev's family trust won a Cayman Islands court ruling to remove biotech fund manager Apple Tree Partners from controlling a $2.5 billion venture capital fund that is in Chapter 11 bankruptcy proceedings in Delaware. The court appointed two Alvarez & Marsal employees as independent overseers, but the ruling sets up a jurisdictional conflict as the US bankruptcy court has not recognized the new officeholders. Oaktree Capital Management earlier offered at least $65 million in financing to the bankrupt entities, potentially positioning the distressed investor to acquire stakes in the fund's drug-development portfolio companies.MorningstarApple Tree Partners Provides Update Following Recent Cayman Court OrderApple Tree Partners issued a statement clarifying that a July 10 Cayman Court order does not affect its US operations, and its managing director remains Seth Harrison. The company says US courts have not recognized the order's officeholders, and its funding motion aims to keep portfolio companies funded through 2026.BloombergRussian Billionaire Wins Fight to Boot Manager of Biotech Fund - BloombergRussian billionaire Dmitry Rybolovlev's family trust prevailed in its effort to remove the manager of a $2.5 billion bankrupt biotech venture capital fund. A Cayman Islands judge ruled on Friday that Apple Tree Partners, led by Seth Harrison, must immediately relinquish control of the fund. Two employees of Alvarez & Marsal were appointed to oversee the partnership by the Grand Court of the Cayman Islands.Endpoints NewsCayman court says Apple Tree general partner should lose control of venture fundThe Cayman Islands court ruled that Apple Tree Partners, an embattled venture firm, should lose control of its venture fund to its main limited partner. The ruling represents a legal loss for the general partner in a dispute over fund governance. The specific details of the court proceedings and the reasoning behind the decision are not available due to paywall restrictions.ForbesWhy A $2.4 Billion Biotech Fund Filed For Bankruptcy Over $500KApple Tree Partners (ATP), a New York-based life sciences venture capital firm managing approximately $2.4 billion, filed voluntary Chapter 11 petitions in Delaware bankruptcy court on December 9, 2025, despite being solvent with between $1 billion and $10 billion in assets against liabilities of less than $500,000. The filing came four days after a Delaware court ordered ATP's controlling limited partner Rigmora Holdings (the family office of Russian billionaire Dmitry Rybolovlev) to pay approximately $96.9 million, and appears designed to freeze a winding-up trial in the Cayman Islands where Rigmora sought to remove ATP founder Seth Harrison as general partner over allegations of mismanagement and conflicts of interest. ATP's approximately 30 portfolio companies developing treatments for cancer, neurological disorders, and infectious diseases face potential collapse due to the funding freeze, with seven already having filed their own Chapter 11 petitions, while Oaktree Capital Management is reportedly considering a $300 million investment in the bankrupt fund.BioPharma DiveBiotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backerBiotech venture firm Apple Tree Partners (ATP) filed for Chapter 11 bankruptcy in the U.S. to protect funding for its portfolio companies amidst a legal dispute with billionaire Dmitry Rybolovlev's entities, Rigmora Biotech Investor One and Two. The filing follows a Delaware Chancery Court order requiring Rigmora to pay approximately $97 million in withheld funds, which ATP claims are critical to prevent the collapse of its startups. Rigmora counter-sued in the Cayman Islands alleging mismanagement by ATP and described the bankruptcy as a delay tactic to avoid oversight.WsjBiotech Venture Fund Files Bankruptcy Over Battle With Russian BillionaireApple Tree Life Sciences, a fund run by life sciences venture firm Apple Tree Partners, filed for Chapter 11 reorganization in U.S. Bankruptcy Court in Wilmington, Delaware. The fund has assets of more than $1 billion but liabilities of less than $500,000, and filed for bankruptcy months after alleging that Russian billionaire Dmitry Rybolovlev failed to meet financing commitments due to liquidity problems at his family office.FierceBiotechApple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechsTwo affiliates of Apple Tree Partners filed for Chapter 11 bankruptcy in Delaware to continue funding portfolio biotech companies while a funding dispute with a major investor plays out. A Delaware court ruled that ATP's controlling limited partners Rigmora Biotech Investor One and Two must pay $96.9 million in capital calls after ATP sued in May alleging the funds withheld funds for 18 months, warning that portfolio companies faced imminent collapse with layoffs already occurring. ATP's estimated assets range between $1 billion and $10 billion while the restructuring is designed to allow its ~16 portfolio biotechs to continue operations during reorganization.